Sign in

CIK 0001651308 · Large accelerated filer

BeOne Medicines Ltd.

Sign in to watch
Ticker
BEIGF
Exchange
Nasdaq, OTC
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
operating
EIN
981209416
Phone
41-616851900
Business address
C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
Former names
BeiGene, Ltd.

Securities

  • ONC American Depositary Shares Nasdaq
  • BEIGF Common stock OTC
  1. 144 Insider Sale of Securities
  2. 144 Insider Sale of Securities
  3. 144 Insider Sale of Securities
  4. 144 Insider Sale of Securities
  5. 4 Open-market sale Principal Accounting Officer sold 134 shares at $258.36 ($34,620)
  6. 4 Grant or award SVP, General Counsel acquired 46,878 shares (grant or award)
  7. 4 Grant or award Chief Financial Officer acquired 63,674 shares (grant or award)
  8. 4 Grant or award Global Head of R&D acquired 86,359 shares (grant or award)
  9. 4 Grant or award President and COO acquired 123,370 shares (grant or award)
  10. 4 Planned sale Director sold 41,760 shares at an average $262.82 ($10,975,316)
  11. 4 Grant or award Chief Executive Officer acquired 185,055 shares (grant or award)
  12. 4 Other disposition Director disposed of 29,614 shares (other)
  13. 144 Insider Sale of Securities
  14. 4 Open-market sale SVP, General Counsel sold 700 shares at an average $256.11 ($179,280)
  15. 4 Open-market sale Global Head of R&D sold 1,402 shares at an average $252.39 ($353,853)
  16. 4 Open-market sale President and COO sold 1,934 shares at an average $253.15 ($489,591)
  17. 4 Open-market sale Chief Executive Officer sold 5,127 shares at an average $252.77 ($1,295,946)
  18. CORRESP Other Correspondence Between Filers and SEC Staff
  19. 144 Insider Sale of Securities
  20. 144 Insider Sale of Securities

Page 11 of 64 · 1,278 filings